Serina Therapeutics
SER on NYSEAmerican. Market value $35m.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
None of the long-term investors we follow own it. 27 funds in all.
Largest holders overall
- Sio Capital Management$2m
- Vanguard Capital Management$314,664
- Waverly Advisors$130,934
- Geode Capital Management$98,955Cut
- Keel Point$41,726
- Northern Trust$40,296New
- Vanguard Fiduciary Trust$38,817
- Avidian Wealth Enterprises$36,472
- Jane Street Group$29,962Cut
- State Street$24,751
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
2 investors own more than 5%.
- Juvenescence LimitedPassive investorat least 27.3%(filed with 1 related holder)Since 20 March 2026
- Sio Capital Management, LLCPassive investor7.9%+1.2 ptsSince 30 September 2026
| Holder | Stake | Since | |
|---|---|---|---|
Juvenescence Limited Passive investor | at least 27.3% (filed with 1 related holder) | 20 March 2026 | |
Sio Capital Management, LLC Passive investor | 7.9%+1.2 pts | 30 September 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 4 insiders bought $77,955 of shares on the open market. 1 sold $335,127, $335,127 of it under preset trading plans.
- Brannan Stephen K.DirectorBought
- Date
- 7 July 2026
- Shares
- 1,000
- Price
- $2.03
- Value
- $2,030
- WILSON KAREN JDirectorBought
- Date
- 12 June 2026
- Shares
- 5,000
- Price
- $1.77
- Value
- $8,850
- WILSON KAREN JDirectorBought
- Date
- 11 June 2026
- Shares
- 5,100
- Price
- $1.75
- Value
- $8,925
- Venkatesan JayDirectorBought
- Date
- 22 May 2026
- Shares
- 589
- Price
- $1.78
- Value
- $1,048
- WILSON KAREN JDirectorBought
- Date
- 22 May 2026
- Shares
- 10,000
- Price
- $1.93
- Value
- $19,300
- WILSON KAREN JDirectorBought
- Date
- 21 May 2026
- Shares
- 10,000
- Price
- $1.77
- Value
- $17,700
- Marshall Richard PeterDirectorBought
- Date
- 19 May 2026
- Shares
- 12,183
- Price
- $1.65
- Value
- $20,102
- Moreadith RandallChief Scientific OfficerSoldunder a preset trading plan
- Date
- 23 March 2026
- Shares
- 6,500
- Price
- $2.86
- Value
- $18,590
- Moreadith RandallChief Scientific OfficerSoldunder a preset trading plan
- Date
- 19 March 2026
- Shares
- 39,000
- Price
- $2.50
- Value
- $97,500
- Moreadith RandallChief Scientific OfficerSoldunder a preset trading plan
- Date
- 2 February 2026
- Shares
- 6,500
- Price
- $3.03
- Value
- $19,695
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 7 July 2026 | Brannan Stephen K. Director | Bought | 1,000 | $2.03 | $2,030 |
| 12 June 2026 | WILSON KAREN J Director | Bought | 5,000 | $1.77 | $8,850 |
| 11 June 2026 | WILSON KAREN J Director | Bought | 5,100 | $1.75 | $8,925 |
| 22 May 2026 | Venkatesan Jay Director | Bought | 589 | $1.78 | $1,048 |
| 22 May 2026 | WILSON KAREN J Director | Bought | 10,000 | $1.93 | $19,300 |
| 21 May 2026 | WILSON KAREN J Director | Bought | 10,000 | $1.77 | $17,700 |
| 19 May 2026 | Marshall Richard Peter Director | Bought | 12,183 | $1.65 | $20,102 |
| 23 March 2026 | Moreadith Randall Chief Scientific Officer | Sold under a preset trading plan | 6,500 | $2.86 | $18,590 |
| 19 March 2026 | Moreadith Randall Chief Scientific Officer | Sold under a preset trading plan | 39,000 | $2.50 | $97,500 |
| 2 February 2026 | Moreadith Randall Chief Scientific Officer | Sold under a preset trading plan | 6,500 | $3.03 | $19,695 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Serina Therapeutics’ filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 25 Mar 2026, plus the 10-Q filed 12 Nov 2026 and 10 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“As such, there is substantial doubt about the Company’s ability to continue as a going concern.”
Show the full paragraph
Management believes that its cash and cash equivalents of $ 19.4 million as of September 30, 2026 are not expected to be sufficient to satisfy the Company’s anticipated operating and other funding requirements for the twelve months from the issuance of these unaudited condensed consolidated interim financial statements. As such, there is substantial doubt about the Company’s ability to continue as a going concern.
From the 10-Q filed 12 November 2026, Part I, Item 1. Financial Statements. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.